<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I: Electron Capture Dissociation for Radiofrequency Ion Trap MS</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>07/01/2008</AwardEffectiveDate>
<AwardExpirationDate>07/31/2009</AwardExpirationDate>
<AwardTotalIntnAmount>0.00</AwardTotalIntnAmount>
<AwardAmount>99991</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>15030000</Code>
<Directorate>
<Abbreviation>TIP</Abbreviation>
<LongName>Dir for Tech, Innovation, &amp; Partnerships</LongName>
</Directorate>
<Division>
<Abbreviation>TI</Abbreviation>
<LongName>Translational Impacts</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Gregory T. Baxter</SignBlockName>
<PO_EMAI/>
<PO_PHON/>
</ProgramOfficer>
<AbstractNarration>This Small Business Innovation Research Phase I project will test the feasibility of an electron capture dissociation (ECD) method for radio-frequency (RF) ion trap mass spectrometers. ECD has emerged as a powerful means to fragment peptide and protein bonds in a manner that can reveal details of post-translational modifications (PTMs). ECD is difficult to implement in RF driven mass analyzers, such as quadrupole and linear ion traps, because the RF fields drive electrons to excess energy and out of the trap. This research demonstrates the feasibility for an ECD method for ion traps using a method of gating the RF off for short periods of time, while introducing low-energy electrons to achieve ECD. &lt;br/&gt;&lt;br/&gt;The broader impacts of this research are in healthcare and disease control. Studying the entire complement of proteins expressed by a particular cell, organism or tissue at a given time and under a specific set of environmental conditions will require developing new automated and high-speed methods for analyzing the protein content of cell lines. The proposed ECD method for ion traps will lead to accurate identification of protein structure including PTM sites. This diagnostic capability has the potential to provide systematic searches for biomarkers. Studies of cancer cell lines can reveal signatures of cancerous cells that can serve as biomarkers for actual diagnosis. The economic impacts in terms of increased productivity and decreased burden on the health care system are substantial. &lt;br/&gt;&lt;br/&gt;&lt;br/&gt;</AbstractNarration>
<MinAmdLetterDate>04/14/2008</MinAmdLetterDate>
<MaxAmdLetterDate>01/15/2009</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.084</CFDA_NUM>
<NSF_PAR_USE_FLAG>0</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>0810794</AwardID>
<Investigator>
<FirstName>Jack</FirstName>
<LastName>Syage</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Jack Syage</PI_FULL_NAME>
<EmailAddress>jsyage@syagen.com</EmailAddress>
<PI_PHON>7147270522</PI_PHON>
<NSF_ID>000153712</NSF_ID>
<StartDate>04/14/2008</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>SYAGEN TECHNOLOGY INC</Name>
<CityName>TUSTIN</CityName>
<ZipCode>927806461</ZipCode>
<PhoneNumber>7142584400</PhoneNumber>
<StreetAddress>1411 WARNER AVE STE D</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>California</StateName>
<StateCode>CA</StateCode>
<CONGRESSDISTRICT>45</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>CA45</CONGRESS_DISTRICT_ORG>
<ORG_UEI_NUM/>
<ORG_LGL_BUS_NAME/>
<ORG_PRNT_UEI_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[SYAGEN TECHNOLOGY INC]]></Name>
<CityName>TUSTIN</CityName>
<StateCode>CA</StateCode>
<ZipCode>927806461</ZipCode>
<StreetAddress><![CDATA[1411 WARNER AVE STE D]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>California</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>45</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>CA45</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<FoaInformation>
<Code>0308000</Code>
<Name>Industrial Technology</Name>
</FoaInformation>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>1517</Code>
<Text>ELECT, PHOTONICS, &amp; DEVICE TEC</Text>
</ProgramReference>
<ProgramReference>
<Code>9181</Code>
<Text>BIOPROCESSING/BIOMOLECULAR MATERIALS</Text>
</ProgramReference>
<ProgramReference>
<Code>9267</Code>
<Text>INSTRUMENTATION &amp; LAB IMPROVE.</Text>
</ProgramReference>
<ProgramReference>
<Code>BIOT</Code>
<Text>BIOTECHNOLOGY</Text>
</ProgramReference>
<Appropriation>
<Code>0108</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Appropriation>
<Code>0109</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Fund>
<Code>01000809DB</Code>
<Name><![CDATA[NSF RESEARCH & RELATED ACTIVIT]]></Name>
<FUND_SYMB_ID>040100</FUND_SYMB_ID>
</Fund>
<Fund>
<Code>01000910DB</Code>
<Name><![CDATA[NSF RESEARCH & RELATED ACTIVIT]]></Name>
<FUND_SYMB_ID>040100</FUND_SYMB_ID>
</Fund>
<FUND_OBLG>2008~99991</FUND_OBLG>
<FUND_OBLG>2009~39818</FUND_OBLG>
</Award>
</rootTag>
